Karyopharm Therapeutics to Participate in Piper Sandler's Annual Healthcare Conference

Karyopharm Therapeutics at the Piper Sandler Healthcare Conference

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a pivotal player in the pharmaceutical industry, will be featuring prominently at the upcoming Piper Sandler 37th Annual Healthcare Conference. Scheduled for December 4, 2025, at 10:30 a.m. ET, the event will take place in New York, NY, where the senior management team is set to partake in a fireside chat.

About the Event

Attendees will be able to watch the live stream of the discussion via the Investor Relations section of Karyopharm’s official website. This chat will delve into the company’s innovative pipeline, including its flagship product, XPOVIO® (selinexor), a unique oral exportin 1 (XPO1) inhibitor. Following the live conversation, the webcast will also be accessible for replay, ensuring wider reach and engagement with stakeholders.

Karyopharm's Impact

Karyopharm is renowned for its dedication to developing groundbreaking cancer therapies, driven by profound respect for patients' courage and tenacity. The company is notably the leader in oral medications that tackle nuclear export dysregulation, a crucial aspect of cancer development.

XPOVIO has not only been approved in the United States for three different oncology indications, but it has also won regulatory approvals in around 50 countries outside the U.S., encompassing vital markets within the European Union, the United Kingdom, and China under the name NEXPOVIO.

Pioneering Research and Development

The company continues to target various cancers with substantial unmet medical needs, including multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Karyopharm's pipeline is focused on delivering compelling therapies for a range of difficult-to-treat malignancies, showcasing their commitment to advancing cancer care.

Karyopharm Therapeutics stands at the forefront of oncological treatments, redefining possibilities through science, dedication, and an unwavering focus on innovation. Their participation in significant conferences like the Piper Sandler event allows for vital discussions about their ongoing projects and future directions, making it a date to watch for keen investors and oncology advocates alike.

For more information about Karyopharm, their progress, and updates on their pipeline, you can visit their official website Karyopharm or follow them on LinkedIn and X at @Karyopharm.